Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 7/2014

01-07-2014 | Adis Drug Evaluation

Denosumab: A Review of its Use in Postmenopausal Women with Osteoporosis

Author: Lesley J. Scott

Published in: Drugs & Aging | Issue 7/2014

Login to get access

Abstract

Subcutaneous denosumab (Prolia® [USA, Europe]; Pralia® [Japan]) once every 6 months is indicated in several countries for the treatment of postmenopausal women with osteoporosis at increased or high risk for fractures (featured indication). In some countries, it is also indicated for use in postmenopausal women who have failed or are intolerant to other osteoporosis treatments. In several international, phase III trials (≤3 years’ duration) involving more than 12,000 women with postmenopausal osteoporosis or low bone mineral density (BMD), including Asian studies, denosumab was an effective and generally well tolerated treatment. Relative to placebo, denosumab treatment significantly reduced the risk of vertebral, nonvertebral and hip fractures and increased BMD at all skeletal sites evaluated, including the lumbar spine and total hip. Furthermore, the benefits of denosumab treatment were generally evident after the first dose and were maintained during up to 8 years of treatment in an ongoing extension study. The tolerability profile of denosumab during this extension phase was consistent with that observed during the initial 3-year FREEDOM trial. At 12 months, denosumab treatment increased BMD at the total hip, lumbar spine and/or femoral neck and reduced markers of bone turnover to a significantly greater extent than oral bisphosphonates in women who were essentially bisphosphonate-naive and in those who had switched from alendronate to denosumab treatment. Further clinical experience, including an ongoing postmarketing safety study, will more fully define the long-term safety of denosumab. In the meantime, denosumab is an important option for the treatment of women with postmenopausal osteoporosis at increased or high-risk of fractures, including in women at increased risk of fracture who are unable to take other osteoporosis treatments.
Literature
1.
2.
Management of osteoporosis in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause. 2010;17(1):25–54.
3.
4.
Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int. 2005;16(Suppl 2):3–7.CrossRef
5.
Chitre M, Shechter D, Grauer A. Denosumab for treatment of postmenopausal osteoporosis. Am J Health Syst Pharm. 2011;68(15):1409–18.PubMedCrossRef
6.
Moen MD, Keam SJ. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging. 2011;28(1):63–82.PubMedCrossRef
7.
Reginster J-Y. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs. 2011;71(1):65–78.PubMedCrossRef
8.
Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19(7):1059–66.PubMedCrossRef
9.
10.
11.
Sutjandra L, Rodriguez RD, Doshi S, et al. Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet. 2011;50(12):793–807.PubMedCrossRef
12.
Kumagai Y, Hasunuma T, Padhi D. A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women. Bone. 2011;49:1101–7.PubMedCrossRef
13.
Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 2007;22(12):1832–41.PubMedCrossRef
14.
McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821–31.PubMedCrossRef
15.
Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222–9.PubMedCrossRef
16.
Miller PD, Wagman RB, Peacock M, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab. 2011;96(2):394–402.PubMedCrossRef
17.
McClung MR, Lewiecki EM, Geller ML, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int. 2013;24(1):227–35.PubMedCentralPubMedCrossRef
18.
Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum appears in N Engl J Med. 2009;361(19):1914]. N Engl J Med. 2009;361(8):756–65.
19.
Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27(3):694–701.PubMedCentralPubMedCrossRef
20.
Ferrari S, Adachi JD, Zapalowski C, et al. Further reduction in the nonvertebral fracture rate is observed following 3 years of denosumab treatment: results with up to 7 years in the FREEDOM extension [abstract no. 1017]. American Society for Bone and Mineral Research Annual Meeting; 4–7 Oct 2013; Baltimore.
21.
Papapoulos S, Lippuner K, Roux C, et al. Eight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the FREEDOM extension [abstract no. LB-M026]. American Society for Bone and Mineral Research Annual Meeting; 4–7 Oct 2013; Baltimore.
22.
Bone HG, Chapurlat R, Brandi M-L, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Met. 2013;98(11):4483–92.CrossRef
23.
Roux C, Lippuner K, Bone HG, et al. Denosumab treatment of postmenopausal women with osteoporosis for 7 years: clinical fracture results from the first 4 years of the FREEDOM extension [abstract no. OP0250]. Ann Rheum Dis. 2013;72(Suppl 3):137.
24.
Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008;93(6):2149–57.PubMedCrossRef
25.
Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96(4):972–80.PubMedCrossRef
26.
Zebaze RM, Libanati C, McClung MR, et al. Denosumab reduces hip cortical porosity in women with osteoporosis [abstract no. 1065]. American Society for Bone and Mineral Research Annual Meeting; 4–7 Oct 2013; Baltimore.
27.
Bolognese MA, Teglbjaerg CS, Zanchetta JR, et al. Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study. J Clin Densitom. 2013;16(2):147–53.PubMedCrossRef
28.
McClung MR, Boonen S, Törring O, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res. 2012;27(1):211–8.PubMedCrossRef
29.
Boonen S, Adachi JD, Man Z, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2011;96(6):1727–36.PubMedCrossRef
30.
Brown JP, Roux C, Törring O, et al. Discontinuation of denosumab and associated fracture incidence: analysis from the fracture reduction evaluation of denosumab in osteoporosis every 6 months (FREEDOM) trial. J Bone Miner Res. 2013;28(4):746–52.PubMedCentralPubMedCrossRef
31.
McCloskey EV, Johansson H, Oden A, et al. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res. 2012;27(7):1480–6.PubMedCrossRef
32.
Jamal SA, Ljunggren O, Stehman-Breen C, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26(8):1829–35.PubMedCrossRef
33.
Simon JA, Recknor C, Moffett AH Jr, et al. Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. Menopause. 2013;20(2):130–7.PubMed
34.
McClung MR, Zanchetta JR, Høiseth A, et al. Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis. J Clin Densitom. 2013;16(2):250–6.PubMedCrossRef
35.
Reid IR, Miller PD, Brown JP, et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res. 2010;25(10):2256–65.PubMedCrossRef
36.
Keaveny TM, McClung MR, Genant HK, et al. Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. J Bone Miner Res. 2014;29(1):158–65.PubMedCrossRef
37.
Genant HK, Keaveny TM, Zapalowski C, et al. Cortical bone parameters at the hip in response to denosumab vs placebo and the clinical relevance of these changes in postmenopausal women with osteoporosis <75 and ≥75 years old [abstract no. SAO400]. American Society for Bone and Mineral Research Annual Meeting; 4–7 Oct 2013; Baltimore.
38.
Eastell R, Christiansen C, Grauer A, et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res. 2011;26(3):530–7.PubMedCrossRef
39.
Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25(1):72–81.PubMedCrossRef
40.
Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24(1):153–61.PubMedCrossRef
41.
Recknor C, Czerwinski E, Bone HG, et al. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol. 2013;121(6):1291–9.PubMedCrossRef
42.
Roux C, Hofbauer LC, Ho PR, et al. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone Miner. 2014;58:48–54.CrossRef
43.
Nakamura T, Matsumoto T, Sugimoto T, et al. Effects of denosumab on fracture risk in Japanese patients with osteoporosis: results of 2-year data from the denosumab fracture intervention randomized placebo controlled trial (DIRECT) [abstract no. 1098]. J Bone Miner Res. 2012;27(Suppl 1):S32.
44.
Silverman S, Viswanathan HN, Yang YC, et al. Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial. Osteoporos Int. 2012;23:1361–9.PubMedCrossRef
45.
Seeman E, Delmas PD, Hanley DA, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res. 2010;25(8):1886–94.PubMedCrossRef
46.
Zebaze RM, Libanati C, Austin M, et al. Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone. 2014;59:173–9.PubMedCrossRef
47.
Kendler DL, Bessette L, Hill CD, et al. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos Int. 2010;21(5):837–46.PubMedCrossRef
48.
Freemantle N, Satram-Hoang S, Tang ET, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2012;23(1):317–26.PubMedCentralPubMedCrossRef
49.
Kendler DL, McClung MR, Freemantle N, et al. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int. 2011;22(6):1725–35.PubMedCrossRef
50.
Kendler DL, Macarios D, Lillestol MJ, et al. Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the denosumab adherence preference satisfaction study. Menopause. 2014;21(1):25–32.PubMedCrossRef
51.
Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013;382(9886):50–6.PubMedCrossRef
52.
Tsai J, Uihlein A, Zhu Y, et al. Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density and microarchitecture: the DATA-HRpQCT Study [abstract no. SA0372]. American Society for Bone and Mineral Research Annual Meeting; 4–7 Oct 2013; Baltimore.
53.
Koh J-M, Oh H-J, Park IH, et al. Efficacy and safety results from a six month double-blind study comparing 60 mg denosumab (DMAb) and placebo in Korean postmenopausal women with osteoporosis [abstract no. SAO386]. American Society for Bone and Mineral Research Annual Meeting; 4–7 Oct 2013; Baltimore.
54.
Nakamura T, Matsumoto T, Sugimoto T, et al. Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis. Osteoporos Int. 2012;23(3):1131–40.PubMedCrossRef
55.
Hiligsmann M, Ethgen O, Bruyère O, et al. Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health. 2009;12(5):687–96.PubMedCrossRef
56.
Parthan A, Kruse M, Yurgin N, et al. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US. Appl Health Econ Health Policy. 2013;11:485–97.PubMedCrossRef
57.
Barbosa E, Machado M, Araujo G, et al. Cost-effectiveness of denosumab in preventing osteoporotic fractures in postmenopausal women from the private healthcare setting perspective in Brazil [abstract no. PMS41]. In: 15th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research; 3–7 Nov 2012; Berlin.
58.
Chau D, Becker DL, Coombes ME, et al. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada. J Med Econ. 2012;15(Suppl 1):3–14.PubMedCrossRef
59.
Ström O, Jönsson B, Kanis JA. Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis. Osteoporos Int. 2013;24(4):1491–502.PubMedCrossRef
60.
Ström O, Borgström F, Kleman M, et al. FRAX® and its applications in health economics: cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone. 2010;47(2):430–7.PubMedCrossRef
61.
Watts NB, Roux C, Modlin JF, et al. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? Osteoporos Int. 2012;23(1):327–37.PubMedCentralPubMedCrossRef
62.
Geller M,Wagman RB, Ho PR, et al. Early findings from Prolia® post-marketing safety surveillance for atypical femoral fracture, osteonecrosis of the jaw, severe symptomatic hypocalcemia, and anaphylaxis [abstract]. International Osteoporosis Federation World Congress on Osteoporosis and 13th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; 2–5 Apr 2014; Seville.
63.
Diz P, Lopez-Cedrun L, Arenaz J, et al. Denosumab-related osteonecrosis of the jaw. J Am Dental Assoc. 2012;143(9):981–4.CrossRef
64.
Rachner TD, Platzbecker U, Felsenberg D, et al. Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy. Mayo Clin Proc. 2013;88(4):418–9.PubMedCrossRef
65.
66.
Hadji P, Papaioannou NA, Gielen E, et al. 12-Month persistence with denosumab (DMab) in women with postmenopausal osteoporosis (PMO): interim results of a 24-month prospective observational study in Germany, Austria, Greece and Belgium [abstract]. International Osteoporosis Federation World Congress on Osteoporosis and 13th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; 2–5 Apr 2014; Seville.
67.
Thompson RN, Armstrong CL, Heyburn G. Bilateral atypical femoral fractures in a patient prescribed denosumab: a case report. Bone. 2014;61(1):44–7.PubMedCrossRef
68.
Drampolos E, Skarpas G, Barbounakis N, et al. Atypical femoral fractures bilaterally in a patient receiving denosumab: a case report. Acta Orthop. 2014;85(1):3–5.CrossRef
69.
Villiers J, Clark DW, Jeswani T, et al. An atraumatic femoral fracture in a patient with rheumatoid arthritis and osteoporosis treated with denosumab. Case Rep Rheumatol. 2013. doi:10.​1155/​2013/​249872.
70.
Adami S, Libanati C, Boonen S, et al. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am. 2012;94(23):2113–9.PubMedCrossRef
71.
Samelson EJ, Miller PD, Christiansen C, et al. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. J Bone Miner Res. 2014;29(2):450–7.PubMedCrossRef
72.
73.
74.
Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in potmenopausal women. Osteoporos Int. 2013;24(1):23–57.PubMedCentralPubMedCrossRef
75.
Miller P, Derman RJ. What is the best balance of benefits and risks among anti-resorptive agents for postmenopausal osteoporosis? Osteoporos Int. 2010;21(11):1793–802.PubMedCrossRef
76.
Silverman S, Christiansen C. Individualizing osteoporosis therapy. Osteoporos Int. 2012;23:797–809.PubMedCrossRef
77.
Diab DL, Watts NB. Postmenopausal osteoporosis. Curr Opin Endocrinol Diabetes Obes. 2013;20:501–9.PubMedCrossRef
78.
Lewiecki EM, Miller PD, Harris ST, et al. Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis. J Clin Densitom. 2013. doi:10.​1016/​j.​jocd.​2013.​09.​018.
79.
Diel IJ, Bergner R, Grötz KA. Adverse effects of bisphosphonates: current issues. J Support Oncol. 2007;5(10):475–82.PubMed
80.
Karlsson L, Lundkvist J, Psachoulia E, et al. Literature review and meta-analysis of persistence with oral bisphosphonates [abstract]. International Osteoporosis Federation World Congress on Osteoporosis and 13th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; 2–5 Apr 2014; Seville.
81.
Hadji P, Intorcia M, Psachoulia E, et al. GRAND 3: the German retrospective cohort analysis on non-adherence in osteoporotic patients: persistence analysis of female patients treated with denosumab [abstract]. International Osteoporosis Federation World Congress on Osteoporosis and 13th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; 2–5 Apr 2014; Seville.
82.
Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013–22.PubMedCrossRef
83.
Badamgarav E, Fitzpatrick LA. A new look at osteoporosis outcomes: the influence of treatment, compliance, persistence, and adherence. Mayo Clin Proc. 2006;81(8):1009–12.PubMedCrossRef
84.
Siris ES, Selby PL, Saag KG, et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009;122 Suppl l:S3–13.
85.
Hadji P, Claus V, Ziller V, et al. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int. 2012;23(1):223–31.PubMedCrossRef
86.
Qi W-X, Tang L-A, He A-N, et al. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol. 2014. doi:10.​1007/​s10147-013-0561-6.
87.
Xue F, Ma H, Stehman-Breen C, et al. Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis. Pharmacoepidemiol Drug Saf. 2013;22:1107–14.PubMed
Metadata
Title
Denosumab: A Review of its Use in Postmenopausal Women with Osteoporosis
Author
Lesley J. Scott
Publication date
01-07-2014
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 7/2014
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-014-0191-3

Other articles of this Issue 7/2014

Drugs & Aging 7/2014 Go to the issue

Leading Article

Pharmacological Treatment of Depression in Older Patients with Chronic Obstructive Pulmonary Disease: Impact on the Course of the Disease and Health Outcomes

Review Article

Decision Making About Change of Medication for Comorbid Disease at the End of Life: An Integrative Review

Original Research Article

Concurrent Use of Drugs and Supplements in a Community-Dwelling Population Aged 50 Years or More: Potential Benefits and Risks

Original Research Article

Appropriateness of Medications Prescribed to Elderly Patients with Advanced Heart Failure and Limited Life Expectancy Who Died During Hospitalization

Original Research Article

Medication Use Before and After Hip Fracture: A Population-Based Cohort and Case-Control Study

Review Article

The Use of Estimated Glomerular Filtration Rate for Dose Adjustment of Medications in the Elderly
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits